Outlook Therapeutics, Inc. (OTLK) |
|
1.025 0.025 (2.5%)
|
03-20 09:44 |
|
Open: |
1.01 |
Pre. Close: |
1 |
|
High:
|
1.04 |
Low:
|
1.01 |
|
Volume:
|
20,094 |
Market Cap:
|
263(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 9:18:34 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.38 One year: 1.51 |
| Support: |
Support1: 0.99 Support2: 0.82 |
| Resistance: |
Resistance1: 1.18 Resistance2: 1.29 |
| Pivot: |
1.06  |
| Moving Average: |
MA(5): 1.01 MA(20): 1.08
MA(100): 1.09 MA(250): 1.22 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 7.4 %D(3): 10.4 |
| RSI: |
RSI(14): 37.4 |
| 52-week: |
High: 2.1 Low: 0.68 |
| Average Vol(K): |
3-Month: 630 (K) 10-Days: 850 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OTLK ] has closed above bottom band by 16.9%. Bollinger Bands are 21.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.06 - 1.06 |
1.06 - 1.07 |
|
Low:
|
0.98 - 0.98 |
0.98 - 0.99 |
|
Close:
|
0.99 - 1 |
1 - 1.01 |
|
Company Description |
|
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. |
Headline News |
Sat, 18 Mar 2023
How Much Is Outlook Therapeutics Inc. (NASDAQ: OTLK) Worth And ... - Marketing Sentinel
Thu, 16 Mar 2023
Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver
Mon, 13 Mar 2023
Outlook Therapeutics® Confirms It Has No Exposure to Silicon ... - GlobeNewswire
Tue, 07 Mar 2023
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is expected to earn ... - Best Stocks
Mon, 06 Mar 2023
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Forecasted to Post ... - MarketBeat
Tue, 14 Feb 2023
Outlook Therapeutics® Reports Financial Results for First Quarter ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
257 (M) |
| Shares Float |
110 (M) |
|
% Held by Insiders
|
60.9 (%) |
|
% Held by Institutions
|
9.4 (%) |
|
Shares Short
|
15,730 (K) |
|
Shares Short P.Month
|
16,020 (K) |
Stock Financials |
|
EPS
|
-0.47 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.08 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-153.6 |
|
Return on Equity (ttm)
|
-990 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.17 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.25 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-57 (M) |
|
Levered Free Cash Flow
|
-33 (M) |
Stock Valuations |
|
PE Ratio
|
-2.13 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-12.5 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-4.53 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-03-17 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
